NEUROCRINE goes like ImClone

[BörsenBot]

Bevorstehender Unternehmenstermin

Bei Neurocrine Biosciences steht morgen der Termin "Quartalsmitteilung" vor Öffnung an.
105 Nutzer haben Neurocrine Biosciences im Portfolio und 198 unserer Nutzer haben Neurocrine Biosciences auf der Watchlist.

Weitere Nachrichten zu Neurocrine Biosciences finden Sie auf der Neurocrine Biosciences Wertpapierdetailseite im Bereich "Neuigkeiten" und unter "Übersicht".
Eine Übersicht aller Unternehmenstermine finden Sie hier.

[surga]

Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference


Live Audio Webcast Wednesday, September 23, 2009

http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-new…

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York.

The live presentation takes place Wednesday, September 23, 2009 at 1:00 p.m. Eastern Time (ET)/10:00 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

.....

[surga]

http://www.reuters.com/article/marketsNews/idCNBNG5258752009…" target="_blank" rel="nofollow ugc noopener">http://www.reuters.com/article/marketsNews/idCNBNG5258752009…



UPDATE 1-Neurocrine Biosciences gets funding of up to $75 mln
Tue Sep 15, 2009 5:35pm EDT

* Says Kingsbridge Capital to provide up to $75 mln

* Shares rise 12 pct

Sept 15 (Reuters) - Neurocrine Biosciences Inc (NBIX.O) said private investment group Kingsbridge Capital Ltd will provide up to $75 million of capital during the next three years through the purchase of newly issued shares of the biopharmaceutical company.

Shares of Neurocrine rose 12 percent to $3.50 in trading after the bell. They closed at $3.13 Tuesday on Nasdaq.

Neurocrine said it has access to capital at its discretion, and the deal does not impose any restrictions on its operating activities or capital-raising alternatives, other than similar committed equity financing facility (CEFF).

The company is not obligated to utilize any of the $75 million available under the CEFF, and there are no minimum commitments or minimum use penalties, Neurocrine said. For the alerts double-click
[ID:nWNAB9893]
(Reporting by Anand Basu in Bangalore; Editing by Deepak Kannan)

[surga]

[surga]

Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results

http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-new…

--Conference Call and Webcast Scheduled for Wednesday, May 6, 2009--

[surga]

Antwort auf Beitrag Nr.: 36.294.580 von zenman am 02.01.09 19:34:20

Danke Zen

[zenman]

Antwort auf Beitrag Nr.: 36.294.427 von surga am 02.01.09 19:17:00

das wünsch ich ebenso

[surga]

Allen NBIX-ler/in, alles Gute zum neuen Jahr 2009

[surga]

mensch, die lassen sich ja Zeit:O
Indiplon Update


http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-sec

The Company met with the FDA in July for an end of review meeting
related to the December 12, 2007 approvable letter for indiplon capsules.
The FDA meeting focused on the three additional requirements outlined in
the approvable letter. After exchange of correspondence regarding meeting
minutes, the Company is awaiting the FDA's final version of these minutes
to determine the next course of action related to indiplon capsules.

[surga]

was ist heute los?